Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
Pipeline News and Updates
Picture

Update for April 5, 2022

4/5/2022

 
Regulatory Update
 
The FDA rejected vadadustat due to cardiovascular, thromboembolic and hepatotoxicity safety concerns and recommended new trials to assess safety.
 
The FDA extended the PDUFA date for vutrisiran by three months to 7/14/2022, for the treatment of transthyretin-mediated (ATTR) amyloidosis, to allow time to review information on a new packaging and labeling facility.
 
The FDA extended the PDUFA date for ublituximab for the treatment of CLL and small lymphocytic lymphoma (SLL) by three months to allow additional time to review new data. The new PDUFA date is 6/25/2022.
 
The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted 6 to 4 to recommend the FDA reject AMX0035 or the treatment of ALS and recommended an additional trial to evaluate efficacy.
 
The FDA accepted the NDA for futibatinib for the treatment of locally advanced or metastatic cholangiocarcinoma harboring FGFR2 gene rearrangements, including gene fusions and set a PDUFA date for 9/30/2022.
 
ImmunoGen submitted a BLA for mirvetuximab soravtansine for the treatment of folate receptor alpha (FRα)-high platinum-resistant ovarian cancer that has been previously treated with one to three prior systemic treatments. 
 
The FDA placed a partial hold on leronlimab HIV trials and a full hold on leronlimab COVID-19 trials in the United States. At the same time, CytoDyn decided to place a hold on its leronlimab COVID-19 Brazilian trial pending review of two cardiac events by the data safety monitoring board.
 
Announced Research Updates
 
Boehringer Ingelheim announced 12-week data for the spesolimab Effisayil 1 trial.
 
Roche announced from the SKYSCRAPER-02 trial, evaluating the addition of tiragolumab to atezolizumab, carboplatin, and etoposide in patients with extensive-stage small cell lung cancer.
 
Cytokinetics announced results from cohort III of the REDWOOD-HCM trial, evaluating aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
 
BMS announced results for the VALOR-HCM trial evaluating the effect of mavacamten on the need for septal reduction therapy in patients with symptomatic obstructive hypertrophic cardiomyopathy. BMS also announced long-term-extension results from the EXPLORER-LTE trial, evaluating mavacamten in the treatment of patients with NYHA Class II or III obstructive hypertrophic cardiomyopathy.
 
Published Research Updates
 
H. pylori eradication with vonoprazan compared to lansoprazole results were published.
 
Harvard researchers discuss the estimated cost effective prices for aducanumab and donanemab in a new analysis.
 
A comparison of anetumab ravtansine to vinorelbine in the treatment of unresectable locally advanced or metastatic disease overexpressing mesothelin was published.
 
Results were published for the GOAL trial evaluating pixantrone plus obinutuzumab in the treatment of diffuse large B-cell lymphoma.
 
The efficacy of CTP-543 in the treatment of moderate to severe alopecia areata was published
 
Results were published for the ROCKIES trial, comparing oral roxadustat to parenteral epoetin alfa in patients with dialysis-dependent CKD.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    July 2023
    June 2023
    May 2023
    April 2023
    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.